Seattle Genetics CEO Clay Siegall in his company’s Bothell laboratory. A drug developed by his company has now gained approval to be used to treat a rare disfiguring blood cancer of the skin. (File photo)

Seattle Genetics CEO Clay Siegall in his company’s Bothell laboratory. A drug developed by his company has now gained approval to be used to treat a rare disfiguring blood cancer of the skin. (File photo)

FDA approves drug developed in Bothell to treat disfiguring blood cancer

Seattle Genetics’ drug Adcetris could be used in treatment of 2,000 a year afflicted with type of lymphoma.

BOTHELL — Seattle Genetics gained approval Thursday for its drug Adcetris to be used to treat a rare disfiguring blood cancer of the skin.

A study found that Adcetris showed far more positive results for test patients than the current drugs in use for cutaneous T-cell lymphoma, said Seattle Genetics CEO Clay B. Siegall.

“It’s such a dramatic difference when we showed the data to doctors they were gasping,” Siegall said. “They were giving these other drugs to patients and they weren’t really helping.”

Cutaneous T-cell lymphoma affects about 2,000 people a year in the U.S. People who have the cancer can have 30, 40 or 50 nodules — abnormal tissue — develop on their skin. There are limited treatment options and no known cure.

Adcetris has been used to treat 40,000 patients with Hodgkin lymphoma and other lymphomas since 2011. Seattle Genetics expects $600 million in global sales this year, Siegall said.

Adcetris targets lymphoma cells and delivers a payload to kill the cancer. The key is the drug is attracted to a protein called CD30 that manifests on lymphoma.

The study conducted on cutaneous T-cell lymphoma involved 131 patients — with half in a control group being treated by one of two existing drugs and the other half being treated with Adcetris. While it’s a small number of patients, the study was statistically meaningful, Siegall said.

The study showed that patients treated with existing medication showed positive results 12.5 percent of the time. Patients who received Adcetris saw positive results 56 percent of the time.

“It was four times the level of response,” Siegall said.

The study did not measure survival rates; that’s something that could be looked at in future studies. The study focused on primary cutaneous anaplastic large cell lymphoma and CD30-expressing mycosis fungoides, the most common subtypes of cutaneous T-cell lymphoma. That’s about 70 percent of cutaneous T-cell lymphoma.

The FDA approval is for second-line treatment, meaning that patients must first be treated with one of the existing drugs.

While the news is welcome for people afflicted with the cancer, Seattle Genetics is hoping to gain another FDA approval in the near future.

It has been put on the fast track to receive approval for Adcetris to be used as front-line treatment with chemotherapy for patients with advanced classical Hodgkin lymphoma. Right now, Adcetris is currently used as second- or third-line treatment when other drugs fail.

If that happens, Seattle Genetics’ signature drug could be used far more in treatments around the U.S. The FDA is evaluating the results of a study called Echelon-1 to determine if Adcetris can be used as a front-line treatment.

“When Wall Street looks at Seattle Genetics the biggest thing they look at is E1 trial for front-line Hodgkin lymphoma,” Siegall said.

Jim Davis: 425-339-3097; jdavis@heraldnet.com; @HBJnews.

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Business

The livery on a Boeing plane. (Christopher Pike / Bloomberg)
Former Lockheed Martin CFO joins Boeing as top financial officer

Boeing’s Chief Financial Officer is being replaced by a former CFO at… Continue reading

Izaac Escalante-Alvarez unpacks a new milling machine at the new Boeing machinists union’s apprentice training center on Friday, June 6, 2025 in Everett, Washington. (Olivia Vanni / The Herald)
Boeing Machinists union training center opens in Everett

The new center aims to give workers an inside track at Boeing jobs.

Some SnoCo stores see shortages after cyberattack on grocery supplier

Some stores, such as Whole Foods and US Foods CHEF’STORE, informed customers that some items may be temporarily unavailable.

People take photos and videos as the first Frontier Arlines flight arrives at Paine Field Airport under a water cannon salute on Monday, June 2, 2025 in Everett, Washington. (Olivia Vanni / The Herald)
Water cannons salute Frontier on its first day at Paine Field

Frontier Airlines joins Alaska Airlines in offering service Snohomish County passengers.

Amit B. Singh, president of Edmonds Community College. 201008
Edmonds College and schools continue diversity programs

Educational diversity programs are alive and well in Snohomish County.

A standard jet fuel, left, burns with extensive smoke output while a 50 percent SAF drop-in jet fuel, right, puts off less smoke during a demonstration of the difference in fuel emissions on Tuesday, March 28, 2023 in Everett, Washington. (Olivia Vanni / The Herald)
Sustainable aviation fuel center gets funding boost

A planned research and development center focused on sustainable aviation… Continue reading

Helion's 6th fusion prototype, Trenta, on display on Tuesday, July 9, 2024 in Everett, Washington. (Olivia Vanni / The Herald)
Helion celebrates smoother path to fusion energy site approval

Helion CEO applauds legislation signed by Gov. Bob Ferguson expected to streamline site selection process.

Pharmacist John Sontra and other employees work on calling customers to get their prescriptions transferred to other stores from the Bartell Drugs Pharmacy on Hoyt Avenue on Wednesday, July 2, 2025 in Everett, Washington. (Olivia Vanni / The Herald)
Bartell Drugs location shutters doors in Everett

John Sontra, a pharmacist at the Hoyt Avenue address for 46 years, said Monday’s closure was emotional.

Wine is illuminated on a large win rack at the center of the main room at Long Shadows Woodinville Tasting Room & Key Club Lounge on Friday, Feb. 28, 2025 in Woodinville, Washington. (Olivia Vanni / The Herald)
Two winery restaurants in Woodinville stand out

You wouldn’t expect to get world-class pizza at a winery,… Continue reading

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.